Biomedical Engineering Reference
In-Depth Information
49. Sharma SK, Bagshawe KD, Melton RG, Sherwood RF. (1992)
Human immune response to monoclonal antibody-enzyme
conjugates in ADEPT pilot clinical trial. Cell Biophys. 21,
109-120.
50. Mayer A, Sharma SK, Tolner B, Minton NP, Purdy D, Amlot P,
et al. (2004) Modifying an immunogenic epitope on a thera-
peutic protein: a step towards an improved system for
antibody-directed enzyme prodrug therapy (ADEPT). Br.
J. Cancer 90, 2402-2410.
51. Cantor JR, Yoo TH, Dixit A, Iverson BL, Forsthuber TG,
Georgiou G. (2000) Therapeutic enzyme deimmunization
by combinatorial T-cell epitope removal using neutral drift.
Proc. Natl. Acad. Sci. USA 108, 1272-1277.
52. Harding FA, Liu AD, Stickler M, Razo OJ, Chin R, Faravashi
N, et al. (2005) A beta-lactamase with reduced immunogenic-
ity for the targeted delivery of chemotherapeutics using anti-
body-directed enzyme prodrug therapy. Mol. Cancer Ther. 4,
1791-1800.
53. Cesaro-Tadic S, Lagos D, Honegger A, Rickard JH, Partridge
LJ, Blackburn GM, et al. (2003) Turnover-based in vitro
selection and evolution of biocatalysts from a fully synthetic
antibody library. Nat. Biotechnol. 21, 679-685.
54. GolynskiyMV, Seelig B. De novo enzymes: fromcomputational
design to mRNA display. Trends Biotechnol. 28, 340-345.
55. Afshar S, Olafsen T, Wu AM, Morrison SL. Characterisation of
an engineered human purine nucleoside phosphorylase fused
to an anti-her2/neu single chain Fv for use in ADEPT. J. Exp.
Clin. Cancer Res. 2009, 28, 147.
56. Afshar S, Asai T, Morrison SL. (2009) Humanized ADEPT
comprised of an engineered human purine nucleoside phos-
phorylase and a tumor targeting peptide for treatment of
cancer. Mol. Cancer Ther. 8, 185-193.
57. Chen KC, Wu SY, Leu YL, Prijovich ZM, Chen BM, Wang
HE, et al. A humanized immunoenzyme with enhanced activity
for glucuronide prodrug activation in the tumor micro-
environment. Bioconjug. Chem. 22, 938-948.
Search WWH ::




Custom Search